Search Results 1001-1010 of 16662 for Psychogenic
This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and ...
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world and a major public health issue in the US. It is ...
Yu H, Bauer B, Lipke GK, Phillips RL, Van Zant G. Apoptosis and hematopoiesis in murine fetal liver. Blood. 1993; 81(2):373-84. View PubMed. PST-20222551.
Part A (dose regimen finding) will allow definition of the maximum tolerated dose (MTD) through dose escalation and possible dose interval modification. In Part ...
This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC).
About this study. The pupose of this study is to determine whether the scales marketed to the consumer are as accurate as the DEXA and InBody 970® for ...
The study has 2 parts, Phase 1a and Phase 1b. The goal of Phase 1a is to gather safety, PK and initial efficacy data for 225Ac-ABD147 to better understand best ...
About this study. A global multicenter, randomized, double-blind, placebo-controlled, pivotal phase III study. To evaluate overall survival (OS) of ...
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
Chen LX, De Mattos A, Bang H, Vu CT, Gandhi M, Alnimri M, Gallay B, Fananapazir G. Angioplasty vs stent in the treatment of transplant renal artery stenosis.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.